Debt plan targets USD 1 billion proceeds; cited USD 252 million India commercial business sale, USD 200 million Corteva rimisoxafen upfront, USD 400 million Tessenderlo investment.
Q2 free cash flow rose to USD 357 million; 2026 free cash flow seen at USD 75 million-USD 225 million, including about USD 170 million restructuring cash spend.